Companies

AXSM · Biotech

Axsome Therapeutics, Inc.

SEC company filings

Reported cash

USD 313,859,000

Sep 30, 2026

SEC filing

Cash and cash equivalents · Restricted cash and marketable securities excluded

Cash verified Nov 16, 2026

Price chart

What changed?

No verified development in tracked sources.

Upcoming catalysts

Next verified event · Clinical readout window

ENGAGE · Q1 2027

Binge Eating Disorder

Phase 3

Timing updated · History

Postponed to a later window

Previous: Q4 2026 · quarter precision

Announced Aug 10, 2026

Previous official source

Binge Eating Disorder: Axsome is conducting the ENGAGE study, a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial evaluating the efficacy and safety of solriamfetol in BED. The Company anticipates topline results from the ENGAGE Phase 3 trial in the fourth quarter of 2026.

Current: Q1 2027 · quarter precision

Announced Nov 2, 2026

Current official source

Binge Eating Disorder: Axsome is conducting the ENGAGE study, a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial evaluating the efficacy and safety of solriamfetol in BED. Target enrollment in the trial has been reached, and the Company anticipates topline results in the first quarter of 2027.

Announced Nov 2, 2026 · Announced window

Official announcement
Source wording

Binge Eating Disorder: Axsome is conducting the ENGAGE study, a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial evaluating the efficacy and safety of solriamfetol in BED. Target enrollment in the trial has been reached, and the Company anticipates topline results in the first quarter of 2027.

FDA target date

AXS-12 · cataplexy in narcolepsy · May 1, 2027

cataplexy in narcolepsy

Announced Nov 2, 2026

Official announcement
Source wording

Narcolepsy: Axsome’s NDA for AXS-12 for the treatment of cataplexy in narcolepsy is currently under review by the FDA. The PDUFA target action date is May 1, 2027.

Clinical readout window

FOCUS-2 · H2 2027

children with ADHD

Phase 3

Announced Nov 2, 2026 · Announced window

Official announcement
Source wording

Attention Deficit Hyperactivity Disorder: Axsome is conducting the FOCUS-2 and FOCUS-3 Phase 3, randomized, double-blind, placebo-controlled, multicenter trials evaluating the efficacy and safety of solriamfetol as a treatment for children and adolescents in ADHD, respectively. The Company anticipates topline results from both studies in the second half of 2027.

Clinical readout window

FOCUS-3 · H2 2027

adolescents with ADHD

Phase 3

Announced Nov 2, 2026 · Announced window

Official announcement
Source wording

Attention Deficit Hyperactivity Disorder: Axsome is conducting the FOCUS-2 and FOCUS-3 Phase 3, randomized, double-blind, placebo-controlled, multicenter trials evaluating the efficacy and safety of solriamfetol as a treatment for children and adolescents in ADHD, respectively. The Company anticipates topline results from both studies in the second half of 2027.

Clinical readout window

SUMMIT · H2 2027

smoking cessation

Phase 3

Announced Nov 2, 2026 · Announced window

Official announcement
Source wording

Smoking Cessation: In August 2026, Axsome initiated the SUMMIT study, a Phase 3, randomized, double-blind, active- and placebo-controlled, multicenter trial to assess the efficacy and safety of AXS-05 for the treatment of smoking cessation. The Company anticipates topline results from the SUMMIT Phase 3 trial in the second half of 2027.

Clinical readout window

SUSTAIN · H2 2027

Shift Work Disorder

Phase 3

Timing updated · History

Narrower timing window

Previous: 2027 · year precision

Announced Aug 10, 2026

Previous official source

Shift Work Disorder: Axsome is conducting the SUSTAIN study, a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial evaluating the efficacy and safety of solriamfetol in SWD in adults. The Company anticipates topline results from the SUSTAIN Phase 3 trial in 2027.

Current: H2 2027 · half precision

Announced Nov 2, 2026

Current official source

Shift Work Disorder: Axsome is conducting the SUSTAIN study, a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial evaluating the efficacy and safety of solriamfetol in SWD in adults. The Company anticipates topline results from SUSTAIN in the second half of 2027.

Announced Nov 2, 2026 · Announced window

Official announcement
Source wording

Shift Work Disorder: Axsome is conducting the SUSTAIN study, a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial evaluating the efficacy and safety of solriamfetol in SWD in adults. The Company anticipates topline results from SUSTAIN in the second half of 2027.

Drug pipeline

20 programs · 36 verified studies

AXS-02

Phase

Phase3

Study status

Unknown
View details

Axsome Therapeutics, Inc.

IndicationOsteoarthritis, Knee

Estimated study completion2020-12

AXS-02 (oral zoledronate)

Phase

Phase3

Study status

Unknown
View details

Axsome Therapeutics, Inc.

IndicationComplex Regional Pain Syndrome; Reflex Sympathetic Dystrophy

Estimated study completion2019-01

AXS-05

Phase

Phase3

Study status

Completed
View details

Axsome Therapeutics, Inc.

IndicationTreatment Resistant Major Depressive Disorder

Actual study completion2020-03-20

AXS-05

Phase

Phase2 / Phase3

Study status

Completed
View details

Axsome Therapeutics, Inc.

IndicationAgitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation,Psychomotor

Actual study completion2020-04-17

AXS-05

Phase

Phase2

Study status

Completed
View details

Axsome Therapeutics, Inc.

IndicationMajor Depressive Disorder

Actual study completion2019-01-07

AXS-05

Phase

Phase3

Study status

Completed
View details

Axsome Therapeutics, Inc.

IndicationDepression; Major Depressive Disorder

Actual study completion2019-12-05

AXS-05

Phase

Phase2

Study status

Completed
View details

Axsome Therapeutics, Inc.

IndicationTreatment Resistant Depression; Major Depressive Disorder

Actual study completion2021-07-30

AXS-05

Phase

Phase3

Study status

Completed
View details

Axsome Therapeutics, Inc.

IndicationAgitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation,Psychomotor

Actual study completion2022-11-21

AXS-05

Phase

Phase2

Study status

Unknown
View details

Axsome Therapeutics, Inc.

IndicationMajor Depressive Disorder; Treatment Resistant Depression

Estimated study completion2021-07

AXS-05

Phase

Phase3

Study status

Completed
View details

Axsome Therapeutics, Inc.

IndicationAgitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation

Actual study completion2024-12-21

1 / 5

5 unverified sponsor matches remain unlinked.

Verified timeline

0 records

No verified developments in tracked sources.